In this review, we focus on different alternative signaling pathways activated in both, BCR::ABL1-mediated CML and JAK2-mediated MPNs, by combining data from in vitro and in vivo-studies that could be used as potential biomarkers of drug resistance. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.